{"id":"W3167211705","doi":"10.1111/bjd.20571","title":"COVID‐19 outcomes in patients with autoimmune blistering disease","year":2021,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Galderma; Regeneron Pharmaceuticals; Celgene; Sanofi; Valeant Pharmaceuticals International; Pfizer","keywords":"Coronavirus disease 2019 (COVID-19); Rituximab; Medicine; Pandemic; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Hydroxychloroquine; Population; Disease; Autoimmune disease; Immunology; Intensive care medicine; Infectious disease (medical specialty); Internal medicine; Virology; Antibody; Environmental health","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00009953701,0.0004054528,0.00198142,0.0005417909,0.0000896169,0.00009805214,0.0003887746,0.0004976496,0.0005899547],"category_scores_gemma":[0.001688815,0.0004076646,0.0004312111,0.0002314595,0.000249233,0.0001691583,0.0001651001,0.002372273,0.00001143575],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003771183,"about_ca_system_score_gemma":0.002593157,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009759844,"about_ca_topic_score_gemma":0.00001950991,"domain_scores_codex":[0.996506,0.0003397469,0.001374046,0.0003784427,0.0007944732,0.0006073204],"domain_scores_gemma":[0.9973187,0.000229236,0.001041035,0.0004702235,0.0004427401,0.0004980158],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003312738,0.0003796949,0.4559169,0.0006637946,0.0003056983,0.3002079,0.00002888637,0.000004095553,5.080902e-7,6.990183e-7,0.2415243,0.0006362502],"study_design_scores_gemma":[0.007821863,0.0001145673,0.761588,0.002334472,0.0005431472,0.06731334,0.00002480001,0.00000244065,0.000001417112,0.00003147252,0.1598744,0.0003501444],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.395558,0.0231916,0.0001146882,0.5787297,0.00108467,0.0008079777,0.0002122754,0.00007639376,0.0002246586],"genre_scores_gemma":[0.4467351,0.0005236635,0.0004979178,0.5496109,0.0004243465,0.00002762643,0.0009541633,0.0002013215,0.001024963],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.3056711,"threshold_uncertainty_score":0.9999293,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01235505301826628,"score_gpt":0.2501066067087263,"score_spread":0.23775155369046,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}